Sabby Management’s Revelation Biosciences REVB Stock Holding History

Sabby Management’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	210,582 +111,150	+112%	+$121K	0.2%	17
2026 Q1	$119K	Sell	99,432 -51,994	-34%	-$101K	0.26%	22
2025 Q4	$484K	Buy	151,426 +99,663	+193%	+$436K	0.7%	13
2025 Q3	$294K	Buy	51,763 +46,281	+844%	+$449K	0.34%	21
2025 Q2	$49.3K	Buy	+5,482	New	+$143K	0.09%	36
2024 Q4	–	Sell	-220	Closed	-$36K	–	41
2024 Q3	$36K	Buy	+220	New	+$53K	0.02%	29
2024 Q1	–	Sell	-70	Closed	-$202K	–	72
2023 Q4	$202K	Hold	70	–	–	0.2%	23
2023 Q3	$278K	Buy	70 +9	+15%	+$39.7K	0.2%	28
2023 Q2	$332K	Buy	61 +30	+97%	+$188K	0.27%	40
2023 Q1	$235K	Buy	+31	New	+$837K	0.2%	42

Other funds holding REVB

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Sabby Management's REVB Position: Q2 2026 in Review

Sabby Management increased its Revelation Biosciences (REVB) stake by 112% in Q2 2026, buying an estimated $121K and bringing the position to 210,582 shares worth $217K. The position accounts for 0.2% of the portfolio, ranked #17.

Sabby Management first reported a position in REVB in Q1 2023 and has held it in 10 quarters since. The position peaked at $484K in Q4 2025. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

Sabby Management held 210,582 shares of Revelation Biosciences worth $217K as of Q2 2026.
Sabby Management bought 111,150 Revelation Biosciences shares in Q2 2026, an estimated $121K.
Revelation Biosciences made up 0.2% of Sabby Management's portfolio in Q2 2026, its #17 holding.
Sabby Management first reported a position in Revelation Biosciences in Q1 2023 and has held it in 10 quarters since.
Sabby Management's Revelation Biosciences position peaked at $484K in Q4 2025.
12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.